ArriVent BioPharma (AVBP) Liabilities and Shareholders Equity (2023 - 2026)

ArriVent BioPharma has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $349.3 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $349.3 million, up 62.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 17.08% YoY), and the FY2025 annual result was $333.2 million, up 21.18% from the prior year.
• Liabilities and Shareholders Equity came in at $349.3 million for Q1 2026 at ArriVent BioPharma, up from $333.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $349.3 million in Q1 2026 to a low of $163.1 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $300.8 million (2024), against an average of $286.1 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 68.57% in 2024 and slumped 34.27% in 2025, its largest moves.
• ArriVent BioPharma's Liabilities and Shareholders Equity stood at $163.1 million in 2023, then jumped by 68.57% to $274.9 million in 2024, then climbed by 21.18% to $333.2 million in 2025, then gained by 4.84% to $349.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $349.3 million (Q1 2026), $333.2 million (Q4 2025), and $326.6 million (Q3 2025), per Business Quant data.